alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
TEENS

COVERAGE TO CARE >>> Prevention

Put Your Health First

Get the preventive services that are right for you!

Take advantage of these and other services available at no cost to you 

under most health coverage.

Behavioral assessments

Vision screening

Alcohol and drug use screening 

Blood pressure 

screening

Depression screening 

STD prevention counseling and 

screening, including HIV and 

cervical dysplasia

Height, weight, and BMI 

measurements

Lead screening for at-risk 

children

Obesity screening and 

counseling

Immunization Vaccines:

• Diphtheria, Tetanus, Pertussis

• Haemophilus influenza type B

• Hepatitis A &B

• HPV

• Inactivated poliovirus

• Influenza (Flu Shot)

• Measles, Mumps, Rubella

• Meningococcal

• Pneumococcal

• Rotavirus

• Varicella (Chicken Pox)

COST TIP

Most preventive services are covered 

at no cost. However, if you receive 

additional services, you may be billed. 

Ask your provider’s office or plan to 

explain any charges.

CMS Product No. 11967

September 2017

For additional resources and a full list of the preventive services covered at no cost sharing 

under most health plans, please visit go.cms.gov/c2c.
§ 1250.44 Drinking utensils and toilet articles. ( a ) No cup, glass, or other drinking utensil which may be used by more than one person shall be provided on any conveyance unless such cup, glass, or drinking utensil shall have been thoroughly cleaned and subjected to effective bactericidal treatment after each individual use.
( b ) Towels, combs, or brushes for common use shall not be provided.
EXHIBIT 99.3

REPORT OF INDEPENDENT ACCOUNTANTS

To the Partners of Hanford L.P.:

In our  opinion,  the  balance  sheets  and the  related  statements  of income,
partners'  equity,  and cash flows of Hanford  L.P.  (not  presented  separately
herein)  present fairly,  in all material  respects,  the financial  position at
December 31, 1998 and 1999, and the results of its operations and its cash flows
for the three years in the period ended  December 31, 1999, in  conformity  with
accounting  principles  generally accepted in the United States. These financial
statements  are  the  responsibility  of  the  Partnership's   management;   our
responsibility  is to express an opinion on these financial  statements based on
our audits.  We conducted  our audits of these  statements  in  accordance  with
auditing standards  generally accepted in the United States,  which require that
we plan and perform the audit to obtain  reasonable  assurance about whether the
financial  statements  are free of  material  misstatement.  An  audit  includes
examining,  on a test basis,  evidence supporting the amounts and disclosures in
the  financial   statements,   assessing  the  accounting  principles  used  and
significant  estimates made by management,  and evaluating the overall financial
statement  presentation.  We believe that our audits provide a reasonable  basis
for the opinion expressed above.

San Fransisco, California                        /s/ Price WaterhouseCoopers LLP
March 3, 2000
<PAGE>   1
                                                                    EXHIBIT 23.4

                  CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the use of our reports
(and to all references to our Firm), as it relates to Aerial Communications,
Inc. and Subsidiaries, included in or made a part of this registration
statement.

                                     ARTHUR ANDERSEN LLP

Chicago, Illinois
December 2, 1999
§ 558.348 Mibolerone. ( a ) *Specifications.* Each 6.5 ounce can contains 30 or 60 micrograms (μg) of mibolerone.
( b ) *Sponsor. See* No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 30 μg for animals weighing up to 25 pounds; 60 μg for animals weighing 26 to 50 pounds; 120 μg for animals weighing 51 to 100 pounds; 180 μg for animals weighing over 100 pounds, or German Shepherds or German Shepherd mix weighing 30 to 80 pounds. Administer daily at least 30 days before expected initiation of heat and continue as long as desired, but for not more than 12 months.
( 2 ) *Indications for use.* For the prevention of estrus (heat) in adult female dogs not intended primarily for breeding purposes.
( 3 ) *Limitations.* Mibolerone should not be used in bitches before first estrous period or in purebred Bedlington terriers. It is not intended for animals being used primarily for breeding purposes. Use orally in adult female dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 45310, July 28, 2020]
<TABLE> <S> <C>

<ARTICLE> 9
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          MAR-31-1999
<PERIOD-START>                             APR-01-1998
<PERIOD-END>                               MAR-31-1999
<EXCHANGE-RATE>                                      1
<CASH>                                          70,811
<INT-BEARING-DEPOSITS>                          37,290
<FED-FUNDS-SOLD>                               171,784
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                  1,521,628
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                      3,506,481
<ALLOWANCE>                                     46,823
<TOTAL-ASSETS>                               5,536,978
<DEPOSITS>                                   3,447,364
<SHORT-TERM>                                         0
<LIABILITIES-OTHER>                          1,264,652
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           760
<OTHER-SE>                                     824,202
<TOTAL-LIABILITIES-AND-EQUITY>               5,536,978
<INTEREST-LOAN>                                237,723
<INTEREST-INVEST>                               74,470
<INTEREST-OTHER>                                24,222
<INTEREST-TOTAL>                               336,415
<INTEREST-DEPOSIT>                             133,146
<INTEREST-EXPENSE>                             167,221
<INTEREST-INCOME-NET>                          169,194
<LOAN-LOSSES>                                   10,698
<SECURITIES-GAINS>                                 390
<EXPENSE-OTHER>                                 98,203
<INCOME-PRETAX>                                 71,616
<INCOME-PRE-EXTRAORDINARY>                      71,616
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    45,175
<EPS-BASIC>                                       0.67
<EPS-DILUTED>                                     0.66
<YIELD-ACTUAL>                                    6.97
<LOANS-NON>                                      7,103
<LOANS-PAST>                                    32,002
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                36,347
<CHARGE-OFFS>                                      597
<RECOVERIES>                                       375
<ALLOWANCE-CLOSE>                               46,823
<ALLOWANCE-DOMESTIC>                            46,823
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
[Federal Register Volume 75, Number 39 (Monday, March 1, 2010)]
[Notices]
[Page 9232]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4180]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of Dietary Supplements (ODS) 2010-2014 Strategic Plan

ACTION: Notice of availability of the ODS Strategic Plan for 2010-2014.

-----------------------------------------------------------------------

SUMMARY: The Office of Dietary Supplements (ODS) at the National 
Institutes of Health (NIH) has completed a strategic planning process 
resulting in the development of the ODS Strategic Plan for 2010-2014, 
entitled Strengthening Knowledge and Understanding of Dietary 
Supplements. The strategic plan is available in pdf format on the ODS 
Web site: http://ods.od.nih.gov/pubs/strategicplan/StrategicPlan2010-2014.pdf.
    The ODS strategic plan was developed after more than a year's worth 
of reflection on its programs, activities, and accomplishments, as well 
as anticipated challenges for the future. It was also shaped by the 
thoughtful input, comments, and advice received from ODS stakeholder 
communities throughout the federal government, academia, the dietary 
supplement industry, consumer advocacy and education groups, and 
interested consumers.

FOR FURTHER INFORMATION CONTACT: Office of Dietary Supplements, 
National Institutes of Health, 6100 Executive Boulevard, Room 3B01, 
Bethesda, MD 20892-7517, E-mail: <a href="/cdn-cgi/l/email-protection#3679726576585f5e18515940"><span class="__cf_email__" data-cfemail="cd82899e8da3a4a5e3aaa2bb">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 

Background

    The mission of the Office of Dietary Supplements (ODS) is to 
strengthen knowledge and understanding of dietary supplements by 
evaluating scientific information, stimulating and supporting research, 
disseminating research results, and educating the public to foster an 
enhanced quality of life and health for the U.S. population. ODS was 
established in the Office of the Director, NIH, in 1995 as a major 
provision of the Dietary Supplement Health and Education Act of 1994 
(DSHEA).

    Dated: February 22, 2010.
Paul M. Coates,
Director, Office of Dietary Supplements, Office of the Director, 
National Institutes of Health.
[FR Doc. 2010-4180 Filed 2-26-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
§ 520.23 Acepromazine. ( a ) *Specifications.* Each tablet contains 10 or 25 milligrams (mg) acepromazine maleate.
( b ) *Sponsors.* See Nos. 000010 and 086117 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 0.25 to 1.0 mg per pound (/lb) body weight orally.
( ii ) *Indications for use.* As an aid in tranquilization and as a preanesthetic agent.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cats* — ( i ) *Amount.* 0.5 to 1.0 mg/lb body weight orally.
( ii ) *Indications for use.* As a tranquilizer.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[75 FR 10165, Mar. 5, 2010, as amended at 88 FR 84699, Dec. 6, 2023]
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.57 Recordkeeping and record retention. ( a ) A sponsor shall maintain adequate records showing the receipt, shipment, or other disposition of the investigational drug. These records are required to include, as appropriate, the name of the investigator to whom the drug is shipped, and the date, quantity, and batch or code mark of each such shipment.
( b ) A sponsor shall maintain complete and accurate records showing any financial interest in § 54.4(a)(3)(i), (a)(3)(ii), (a)(3)(iii), and (a)(3)(iv) of this chapter paid to clinical investigators by the sponsor of the covered study. A sponsor shall also maintain complete and accurate records concerning all other financial interests of investigators subject to part 54 of this chapter.
( c ) A sponsor shall retain the records and reports required by this part for 2 years after a marketing application is approved for the drug; or, if an application is not approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified.
( d ) A sponsor shall retain reserve samples of any test article and reference standard identified in, and used in any of the bioequivalence or bioavailability studies described in, § 320.38 or § 320.63 of this chapter, and release the reserve samples to FDA upon request, in accordance with, and for the period specified in § 320.38.
[52 FR 8831, Mar. 19, 1987, as amended at 52 FR 23031, June 17, 1987; 58 FR 25926, Apr. 28, 1993; 63 FR 5252, Feb. 2, 1998; 67 FR 9586, Mar. 4, 2002]
**Exhibit 31.2**
**Certification Pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, asAmended**
I, Alice M. Voss, certify that:
 1.  I have reviewed this quarterly report on Form 10-Q of Front Range Capital Corporation;  2.  Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading withrespect to the period covered by this quarterly report;  3.  Based on my knowledge, the financial statements, and other financial informationincluded in this quarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, and for, theperiods presented in this quarterly report;  4.  The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and we have:
 a.  Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;  b.  Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and  c.  Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s most recentfiscal quarter that has materially affected, or is reasonably likely to materiallyaffect, the registrant’s internal control over financial reporting.   Date: May 12, 2005 /s/ Alice M. Voss   Alice M. Voss Chief Financial Officer
# L_2019242EN.01002501.xml

| 20.9.2019 | EN | Official Journal of the European Union | L 242/25 |
| --- | --- | --- | --- |

20.9.2019

EN

Official Journal of the European Union

L 242/25

---

COUNCIL DECISION (EU) 2019/1571

of 16 September 2019

appointing a member, proposed by the Federal Republic of Germany, of the Committee of the Regions

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 305 thereof,

Having regard to the proposal of the German Government,

Whereas:

| (1) | On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. On 18 September 2018, by Council Decision (EU) 2018/1271 (4) Ms Beate MERK was replaced by Mr Georg EISENREICH as a member. |
| --- | --- |

(1)

On 26 January 2015, 5 February 2015 and 23 June 2015, the Council adopted Decisions (EU) 2015/116 (1), (EU) 2015/190 (2) and (EU) 2015/994 (3) appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020. On 18 September 2018, by Council Decision (EU) 2018/1271 (4) Ms Beate MERK was replaced by Mr Georg EISENREICH as a member.

| (2) | A member's seat on the Committee of the Regions has become vacant following the end of the term of office of Mr Georg EISENREICH, |
| --- | --- |

(2)

A member's seat on the Committee of the Regions has become vacant following the end of the term of office of Mr Georg EISENREICH,

HAS ADOPTED THIS DECISION:

Article 1

The following is hereby appointed as a member of the Committee of the Regions for the remainder of the current term of office, which runs until 25 January 2020:

| — | Mr Florian HERRMANN, Staatsminister (Freistaat Bayern). |
| --- | --- |

—

Mr Florian HERRMANN, Staatsminister (Freistaat Bayern).

Article 2

This Decision shall enter into force on the date of its adoption.

Done at Brussels, 16 September 2019.

For the Council

The President

T. TUPPURAINEN

---

(1)  Council Decision (EU) 2015/116 of 26 January 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 20, 27.1.2015, p. 42).

1

(2)  Council Decision (EU) 2015/190 of 5 February 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 31, 7.2.2015, p. 25).

2

(3)  Council Decision (EU) 2015/994 of 23 June 2015 appointing the members and alternate members of the Committee of the Regions for the period from 26 January 2015 to 25 January 2020 (OJ L 159, 25.6.2015, p. 70).

3

(4)  Council Decision (EU) 2018/1271 of 18 September 2018 appointing a member, proposed by the Federal Republic of Germany, of the Committee of the Regions (OJ L 238, 21.9.2018, p. 88).

4

---
<PAGE>   1

                                                                    Exhibit 23.2



                        Consent of Independent Auditors


We consent to the incorporation by reference in this Annual Report (Form 10-K)
of Smartflex Systems, Inc. of our report dated February 4, 1999, included in the
1998 Annual Report to Shareholders of Smartflex Systems, Inc.

Our audits also included the financial statement schedule of Smartflex Systems,
Inc., listed in the Index at Item 14(a). This schedule is the responsibility of
the Company's management. Our responsibility is to express an opinion based on
our audits. In our opinion, such consolidated financial statement schedule
referred to above, when considered in relation to the basic consolidated
financial statements taken as a whole, presents fairly in all material respects
the information set forth therein.

We also consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 33-95434) pertaining to the 1995 Equity Incentive Plan of
Smartflex Systems, Inc., the Registration Statement (Form S-8 No. 33-95358)
pertaining to the 1995 Employee Stock Purchase Plan of Smartflex Systems, Inc.
and the Registration Statement (Form S-8 No. 33-95372) pertaining to the 1993
Equity Incentive Plan of Smartflex Systems, Inc. of our report dated February 4,
1999 with respect to the consolidated financial statements incorporated herein
by reference, and our report included in the preceding paragraph with respect to
the financial statement schedule included in this Annual Report (Form 10-K) of
Smartflex Systems, Inc.


                                                /s/ Ernst & Young LLP


Orange County, California
April 26, 1999
EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of National Medical Health Card Systems, Inc. (the "Company") on Form 10-Q for the period ending
December 31, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James J. Bigl, Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)   The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)   The
information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

|/s/JAMES J. BIGLJames J. Bigl
Chief Executive Officer
February 19, 2004 |  | 
|----------------------------------------------------------------------- |  | 
|                                                                        |  | 

---

QuickLinks
EXHIBIT 10.118

[SOUTHWALL
TECHNOLOGIES LETTERHEAD]

May 15,
2002

Mr. Naoto
Shiraiwa
Vice President & Manager
UFJ Bank
One Front Street, Suite 1800
San Francisco, California 94111
U.S.A.

Re:
Credit Agreement dated as of May 6, 1997 between Southwall Technologies Inc. ("STI") and the Sanwa Bank Limited ("Credit Agreement"), and to the First Amendment to the Credit
Agreement dated November 8, 1999 between Southwall Technologies Inc. and the Sanwa Bank Limited.

Dear
Mr. Shiraiwa,

On
May 9, 2002, Teijin waived any defaults under Article 5.1 of the Guarantee Agreement that may exist through and including September 30, 2003 arising out of STI's failure to
comply with the financial covenants of the Minimum Quick Ratio, Tangible Net Worth Amount and Maximum Debt/Tangible Net Worth in article 4-(1) of the Guarantee Agreement. A copy of that waiver
is attached as Exhibit A of this letter.

Southwall
Technologies respectively requests the UFJ Bank Limited (formerly Sanwa Bank Limited) waive any Default or Event of Default pursuant to Section 7.01(h) of the above referenced Credit
Agreement for STI's failure to comply with the above terms of the Teijin Guaranty Agreement.

Your
agreement to acknowledge that Teijin's waiver is sufficient to remedy the default in the above referenced Credit Agreement will allow Southwall to classify a portion of its debt to UFJ Bank as
long term debt in its 10-Q filing. This 10-Q will be added to the amended S-1 filed with the SEC for the sale of additional shares of its Common Stock.

Thank
you for your consideration of this request.

Sincerely,

/s/THOMAS G. HOOD

Thomas
G. Hood
President and Chief Executive Officer

Enclosure

Acknowledged:

|/s/NAOTO SHIRAIWASigned
UFJ Bank Ltd. |  | May 16, 2002Date
|------------------------------------- |  | ----------------

---

QuickLinks
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Women at Work: A Century of Industrial Change

              																	United States. Women's Bureau					 and 	Nelson, Eleanor, 1906-. 						*Women at Work: A Century of Industrial Change : Women's Bureau Bulletin, No. 115*,												Washington: 								Govt. Print. Off., 										1933,									https://fraser.stlouisfed.org/title/5413,			accessed on September 25, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER